CSI Market
Sign In | Register

Curative Biosciences (BEVS) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access BEVS Annual Cash Flow →
Changes in quarterly cash flow trends offer perspective on how Curative Biosciences funds operations, investments, and shareholder returns.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2018)
9 Months 		(Dec 31 2017) (Sep 30 2017) (Jun 30 2017) (Mar 31 2017)
Operating Activities
Income-0.50
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.00
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Common Stock Issued For Directors Fees-
Common Stock Issued For License-
Increase In Directors Fees-
Increase In Accrued Payroll Taxes-
Increase In Account Payable-
Shares Issued Of Salaries-
Shares Issued For Officers Other Loans And Accounts Payble-
Shares Issued For Drink License-
Amortization Of Websites And Drink License-
Share Based Goods And Nonemployee Services Transaction Cash Flow Effects-
Shares To Pay Settlement-
Shares Issued For Services Directors Fees Payable-
Stock Issued During Period Value Issued For Services0.43
Shares Issued For Directors Fees-
Shares Issued For Services Related Parties-
Net Investment Income-
Decrease In Sales Tax Payable-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Employee Related Liabilities0.00
Increase (Decrease) in Accounts Payable-0.01
Increase (Decrease) in Accrued Liabilities0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense0.00
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-0.08
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Other Investments-0.01
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.01
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.09
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Stock Issued-
Subscription Revenue-
Net Increase In Cash-
Net Decrease In Cash-
Net Decrease Increase In Cash-
Directors Loans Advanced-
Bank Overdraft-
Cash Ending Of Period-
Shares Issued For Services-
Shares Issued For Shareholder Loans-
Share Issued For Account Payable-
Loans And Leases Receivable Related Parties Collections-
Shares Issued To Pay Shareholder Loans-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.09
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-0.08
Total Cash Flow0.00
4 historic quarters locked

Sign in to unlock the full Curative Biosciences cash flow history.

Sign In Create Free Account

About BEVS Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.